#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hyperphagia Chronic cutaneous lupus erythematosus Transient ischaemic attack Hepato-lenticular degeneration Philadelphia positive acute lymphocytic leukaemia Diffuse large B-cell lymphoma refractory Neonatal asphyxia Hepatitis B Follicle centre lymphoma follicular grade I, II – III Cervix carcinoma Myelodysplastic syndrome Liposarcoma metastatic Piriformis syndrome Cryoglobulinaemia Immune thrombocytopenia More trials…

    Learn about Rare Diseases

    Leiomyosarcoma recurrent – Diagnostics Chronic granulomatous disease – Basic Information Primary immunodeficiency syndrome – Trials in Disease Bronchopulmonary dysplasia Optic glioma – Diagnostics Leiomyosarcoma recurrent – Basic Information Loeys-Dietz syndrome – Trials in Disease Familial haemophagocytic lymphohistiocytosis Inclusion body myositis – Basic Information Proteus syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Human Cancellous Bone Laronidase Sxr1096 Nms-03592088 Fluoroethyltyrosine F-18 Dasatinib PETHIDINE HYDROCHLORIDE Colesevelam Afamelanotide DICLOFENAC POTASSIUM Delandistrogene Moxeparvovec Estradiol Valerate Naloxone Hydrochloride [18F]CPFPX Alisertib Sodium Etravirine Ipilimumab Peginterferon Beta-1A Chlorpromazine Hydrochloride Tenofovir Disoproxil Fumarate More therapies…

    Learn about Your Condition

    Pancreatic neoplasm Head and neck cancer Chronic disease Circulatory collapse Influenza Neuromyopathy Venous thrombosis Sepsis Testicular germ cell tumour Body mass index increased Lupus nephritis Hypertension Niemann-Pick disease Skin neoplasm excision Gaucher's disease type I More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Slovakia

  • A study to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight and type 2 diabetes

    Recruiting

    3 1
    Investigated Drugs:
    • LY3841136 SODIUM
    Czechia Germany Poland Slovakia Spain
  • Study of mirikizumab and tirzepatide for adults with moderate to severe Crohn’s disease who are overweight or obese

    Recruiting

    3 1
    Investigated Drugs:
    • Mirikizumab
    • Tirzepatide
    Austria Belgium Bulgaria Czechia Denmark France +9
  • A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

    Recruiting

    3 1 1
    Investigated Drugs:
    • Azd5004
    • Dapagliflozin
    Czechia Denmark Germany Greece Hungary Poland +1
  • Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Czechia France Germany Greece +9
  • Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Bulgaria Czechia Denmark France +11
  • Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

    Recruiting

    4 1
    Investigated Drugs:
    • LUNSEKIMIG
    Czechia Germany Greece Lithuania The Netherlands Norway +4
1 2 3 … 80
Next Page

Find Clinical Trials in Your Selected Region and City

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Prednisolone Prednisone Semaglutide Pembrolizumab Upadacitinib Guselkumab Dexamethasone Dapagliflozin Cyclophosphamide Aflibercept Remibrutinib Enzalutamide Doxorubicin Hydrochloride Vincristine Sulfate Rituximab Risankizumab Cagrilintide Glycopyrronium Bromide Duvakitug Etoposide Salbutamol Sodium Chloride Palbociclib Formoterol Fumarate Dihydrate Baxdrostat Iptacopan Hydrocortisone Cisplatin Carboplatin Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues Show more

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

Abdominal infection Acromegaly Acute coronary syndrome Acute haemorrhagic ulcerative colitis Acute lymphocytic leukaemia Acute myeloid leukaemia Acute myocardial infarction Acute respiratory failure Adenocarcinoma pancreas Age-related macular degeneration Agitation Alopecia areata Alport's syndrome Anaemia of chronic disease Anaplastic large cell lymphoma T- and null-cell types Angina pectoris Ankylosing spondylitis Antibiotic therapy Arteriosclerosis Asthma Ataxia telangiectasia Atrial fibrillation Atypical haemolytic uraemic syndrome Axial spondyloarthritis B-cell lymphoma B-cell small lymphocytic lymphoma B-cell type acute leukaemia Bacterial infection Bacterial vaginosis Bipolar I disorder Breast cancer Breast cancer metastatic Bronchiectasis C3 glomerulopathy Cachexia Cardiac ablation Cardiac failure Cardiac failure chronic Cardiomyopathy Cardiovascular disorder Central nervous system melanoma Cerebrovascular accident prophylaxis Chronic cutaneous lupus erythematosus Chronic inflammatory demyelinating polyradiculoneuropathy Chronic kidney disease Chronic lymphocytic leukaemia Chronic myeloid leukaemia Chronic myelomonocytic leukaemia Chronic obstructive pulmonary disease Chronic spontaneous urticaria Coeliac disease Cold urticaria Colitis ulcerative Colorectal adenocarcinoma Colorectal cancer Colorectal cancer metastatic Conjunctivitis allergic Contraception Cough COVID-19 Crohn's disease Cutaneous lupus erythematosus Cystic fibrosis Dedifferentiated liposarcoma Deep vein thrombosis Dementia Alzheimer's type Dementia of the Alzheimer's type uncomplicated Dementia of the Alzheimer's type with delusions Dermatitis atopic Dermatomyositis Diabetic foot infection Diabetic retinal oedema Diabetic retinopathy Diffuse large B-cell lymphoma Dry age-related macular degeneration Dry eye Dyslipidaemia EGFR gene mutation Endocrine ophthalmopathy Eosinophilic oesophagitis Erosive oesophagitis Erythema migrans Ewing's sarcoma Factor IX deficiency Factor VIII deficiency Familial hypertriglyceridaemia Focal segmental glomerulosclerosis Follicle centre lymphoma follicular grade I II - III refractory Follicle centre lymphoma follicular grade I, II - III Follicular lymphoma Gastrointestinal melanoma Generalised anxiety disorder Generalised tonic-clonic seizure Germ cell cancer Glomerulonephritis membranoproliferative Glomerulonephritis minimal lesion Haematological infection Haematological malignancy Hepatic cirrhosis Hepatoblastoma Hepatocellular carcinoma HER2 positive biliary tract cancer Hereditary angioedema Hereditary angioedema with C1 esterase inhibitor deficiency Hidradenitis Hodgkin's disease Hormone receptor positive HER2 negative breast cancer Hormone-dependent prostate cancer Hormone-refractory prostate cancer Huntington's disease Hypercholesterolaemia Hyperchylomicronaemia Hyperkalaemia Hypertension Hypertriglyceridaemia Hypophosphatasia Idiopathic inflammatory myopathy IgA nephropathy Inflammatory myofibroblastic tumour Iron deficiency Ischaemic stroke Juvenile absence epilepsy Leiomyosarcoma Liposarcoma metastatic Lung disorder Macular oedema Major depression Malignant melanoma Malignant melanoma of eyelid Malignant melanoma stage III Malignant melanoma stage IV Mania Melanoma recurrent Metabolic dysfunction-associated steatohepatitis Metastatic malignant melanoma Migraine Migraine with aura Migraine without aura Multifocal motor neuropathy Multiple sclerosis Multiple sclerosis relapse Myelodysplastic syndrome Myopia Neonatal alloimmune thrombocytopenia Neoplasm Neoplasm malignant Neovascular age-related macular degeneration Nephrogenic anaemia Neuroblastoma Neurogenic bladder Non-alcoholic steatohepatitis Non-Hodgkin's lymphoma Non-small cell lung cancer Non-small cell lung cancer metastatic Non-small cell lung cancer stage II Non-small cell lung cancer stage III Non-small cell lung cancer stage IV Obesity Oropharyngeal squamous cell carcinoma Osteogenesis imperfecta Osteoporosis postmenopausal Ovarian cancer Overweight Pancreatic carcinoma metastatic Paresis Parkinson's disease Partial seizures Pemphigoid Peripheral arterial occlusive disease Petit mal epilepsy Plasma cell myeloma Plasma cell myeloma refractory Pneumonia Pneumonia bacterial Polymyositis Primary biliary cholangitis Primary immunodeficiency syndrome Primary progressive multiple sclerosis Progressive relapsing multiple sclerosis Prostate cancer Prostate cancer metastatic Prostate cancer recurrent Psoriasis Psoriatic arthropathy Psychotic disorder Pulmonary arterial hypertension Pyelonephritis Pyelonephritis acute Relapsing multiple sclerosis Relapsing-remitting multiple sclerosis Renal cell carcinoma Renal disorder Respiratory syncytial virus infection Retinal vein occlusion Retinopathy of prematurity Rhabdomyosarcoma Rheumatoid arthritis Schizophrenia Secondary progressive multiple sclerosis Sepsis Sjogren's syndrome Skin cancer Skin ulcer Squamous cell carcinoma of head and neck Status epilepticus Subacute cutaneous lupus erythematosus Systemic lupus erythematosus Tardive dyskinesia Thrombolysis Thrombosis prophylaxis Transient ischaemic attack Transitional cell carcinoma Triple negative breast cancer Type 1 diabetes mellitus Type 2 diabetes mellitus Type IIa hyperlipidaemia Urinary tract infection Urticaria cholinergic Urticaria chronic Vitiligo

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.

Numer nieprawidłowy!
Numer nieprawidłowy!